CA2078118A1 - Cc-1065 analogs - Google Patents
Cc-1065 analogsInfo
- Publication number
- CA2078118A1 CA2078118A1 CA2078118A CA2078118A CA2078118A1 CA 2078118 A1 CA2078118 A1 CA 2078118A1 CA 2078118 A CA2078118 A CA 2078118A CA 2078118 A CA2078118 A CA 2078118A CA 2078118 A1 CA2078118 A1 CA 2078118A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compounds
- human
- linked
- analogs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
This invention provides some new synthetically obtained compounds of formula I
and II
(see formula I and II) which are useful as chemical intermediates. Representative formula I or II
compounds have also been shown to possess useful ranges of antitumor activity in standard laboratory anima) tests.
In addition, the compounds of formula I or II can be linked to monoclonal antibodies, either directly or via known linking group, as a means of selectively delivering the CC-1065 analogs (Compounds of Formula I and II) to those target cells expressing the target antigen and thus selectively eliminating those diseased cells from the animal or human.
Further, the compounds of formula I and II can be linked to soluble human CD4 or a soluble human CD4 protein fragment capable of binding to the gp 120 envelope protein of the human immuno- virus and thus eliminate virally infected cells.
and II
(see formula I and II) which are useful as chemical intermediates. Representative formula I or II
compounds have also been shown to possess useful ranges of antitumor activity in standard laboratory anima) tests.
In addition, the compounds of formula I or II can be linked to monoclonal antibodies, either directly or via known linking group, as a means of selectively delivering the CC-1065 analogs (Compounds of Formula I and II) to those target cells expressing the target antigen and thus selectively eliminating those diseased cells from the animal or human.
Further, the compounds of formula I and II can be linked to soluble human CD4 or a soluble human CD4 protein fragment capable of binding to the gp 120 envelope protein of the human immuno- virus and thus eliminate virally infected cells.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51350190A | 1990-04-25 | 1990-04-25 | |
US513,501 | 1990-04-25 | ||
PCT/US1991/002704 WO1991016324A1 (en) | 1990-04-25 | 1991-04-24 | Novel cc-1065 analogs |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2078118A1 true CA2078118A1 (en) | 1991-10-26 |
CA2078118C CA2078118C (en) | 1999-11-16 |
Family
ID=24043550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002078118A Expired - Fee Related CA2078118C (en) | 1990-04-25 | 1991-04-24 | Cc-1065 analogs |
Country Status (7)
Country | Link |
---|---|
US (1) | US5739350A (en) |
EP (1) | EP0527189A1 (en) |
JP (1) | JPH05508394A (en) |
KR (1) | KR100208957B1 (en) |
AU (1) | AU648313B2 (en) |
CA (1) | CA2078118C (en) |
WO (1) | WO1991016324A1 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU640135B2 (en) * | 1990-03-20 | 1993-08-19 | Wellcome Foundation Limited, The | Hetero polycyclic biocidal compounds and their use in medicine |
ES2149768T3 (en) * | 1992-03-25 | 2000-11-16 | Immunogen Inc | CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065. |
US5248691A (en) * | 1992-09-03 | 1993-09-28 | Eli Lilly And Company | Furanoindolines |
ES2074957B1 (en) * | 1993-11-19 | 1996-06-16 | Univ Santiago Compostela | NEW DERIVATIVES OF PIRROLO (3,2-E) INDOL, PROCEDURE FOR ITS PREPARATION AND APPLICATIONS. |
US5786377A (en) * | 1993-11-19 | 1998-07-28 | Universidad De Santiago De Compostela | Pyrrolo 3,2-E!indol derivatives, process for the preparation thereof and applications |
GB9516943D0 (en) * | 1995-08-18 | 1995-10-18 | Cancer Soc Auckland Div Nz Inc | Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs |
DE69734722T2 (en) * | 1996-09-12 | 2006-07-20 | Auckland Uniservices Ltd. | CONDENSED N-ACYLINDOLE AS ANTITUMOROUSE |
US6130237A (en) * | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
JPH1087666A (en) * | 1996-09-18 | 1998-04-07 | Kyorin Pharmaceut Co Ltd | Intermediate for producing duocarmycin sa and its derivative and production thereof |
DE69925133T2 (en) | 1998-08-27 | 2006-01-19 | Spirogen Ltd., Ryde | PYRROLOBENZODIAZEPINE |
GB9818730D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Collections of compounds |
US6909006B1 (en) * | 1999-08-27 | 2005-06-21 | Spirogen Limited | Cyclopropylindole derivatives |
US7589180B2 (en) | 2001-05-11 | 2009-09-15 | Abbott Laboratories Inc. | Specific binding proteins and uses thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
EP1434778A4 (en) * | 2001-05-31 | 2005-07-13 | Medarex Inc | Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
EP1554271A1 (en) * | 2002-10-15 | 2005-07-20 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
GB0226593D0 (en) | 2002-11-14 | 2002-12-24 | Consultants Ltd | Compounds |
GB0321295D0 (en) | 2003-09-11 | 2003-10-15 | Spirogen Ltd | Synthesis of protected pyrrolobenzodiazepines |
ES2384940T3 (en) * | 2004-01-16 | 2012-07-16 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immunokinase |
RU2402548C2 (en) * | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Chemical linkers and conjugates thereof |
BRPI0510909A2 (en) * | 2004-05-19 | 2008-12-16 | Medarex Inc | cytotoxic drug-binder binding compound, pharmaceutical formulation, method for killing a cell and method for retarding or stopping tumor growth |
US20060045877A1 (en) * | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
WO2006089230A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (psma) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
EA016577B1 (en) | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Antibody-drug conjugates and use thereof |
US8124738B2 (en) * | 2005-09-26 | 2012-02-28 | Medarex, Inc. | Human monoclonal antibodies to CD70 |
DK1940789T3 (en) | 2005-10-26 | 2012-03-19 | Medarex Inc | Methods and Compounds for the Preparation of CC-1065 Analogs |
CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
EP1800695A1 (en) * | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
EP1994000B1 (en) * | 2006-02-02 | 2017-08-23 | Syntarga B.V. | Water-soluble cc-1065 analogs and their conjugates |
KR101552735B1 (en) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 22 human antibodies that bind cd22 and uses thereof |
CL2007003622A1 (en) | 2006-12-13 | 2009-08-07 | Medarex Inc | Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method. |
KR20090088946A (en) * | 2006-12-14 | 2009-08-20 | 메다렉스, 인코포레이티드 | Human antibodies that bind cd70 and uses thereof |
TWI412367B (en) | 2006-12-28 | 2013-10-21 | Medarex Llc | Chemical linkers and cleavable substrates and conjugates thereof |
WO2008091701A2 (en) * | 2007-01-25 | 2008-07-31 | Dana-Farber Cancer Institute | Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
CA2678514A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
WO2008115404A1 (en) * | 2007-03-15 | 2008-09-25 | Ludwing Institute For Cancer Research | Treatment method using egfr antibodies and src inhibitors and related formulations |
EP2587263A1 (en) * | 2007-07-25 | 2013-05-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Self coupling recombinant antibody fusion proteins |
EP2173739B1 (en) | 2007-08-01 | 2013-07-31 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
CA2696360C (en) | 2007-08-14 | 2018-11-20 | Ludwig Institute For Cancer Research | Monoclonal antibody targeting the egfr receptor and uses thereof |
WO2009026274A1 (en) | 2007-08-22 | 2009-02-26 | Medarex, Inc. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
PL2195017T3 (en) | 2007-10-01 | 2015-03-31 | Bristol Myers Squibb Co | Human antibodies that bind mesothelin, and uses thereof |
AR069746A1 (en) * | 2007-11-30 | 2010-02-17 | Medarex Inc | ANTI-RG-1 ANTIBODY CONJUGATES |
ES2475201T3 (en) * | 2007-12-26 | 2014-07-10 | Biotest Ag | Agents directed against CD138 and their uses |
HUE024291T2 (en) * | 2007-12-26 | 2016-01-28 | Biotest Ag | Immunoconjugates targeting cd138 and uses thereof |
JP2011507933A (en) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | Methods for reducing cytotoxic side effects and improving efficacy of immune complexes |
MX2010007101A (en) | 2007-12-26 | 2011-07-01 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells. |
DK2281006T3 (en) | 2008-04-30 | 2017-11-06 | Immunogen Inc | CROSS-BONDING AGENTS AND APPLICATIONS THEREOF |
HUE035798T2 (en) * | 2008-11-03 | 2018-05-28 | Syntarga Bv | Cc-1065 analogs and their conjugates |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
US20120231004A1 (en) | 2009-10-13 | 2012-09-13 | Oxford Biotherapeutic Ltd. | Antibodies |
ES2815678T3 (en) | 2010-04-21 | 2021-03-30 | Syntarga Bv | Conjugates of CC-1065 Analogs and Bifunctional Linkers |
US8877892B2 (en) * | 2011-03-15 | 2014-11-04 | Innova Biosciences Limited | Conjugation reactions |
US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
ES2640960T3 (en) | 2011-06-28 | 2017-11-07 | Oxford Biotherapeutics Ltd. | Antibodies for ADP-ribosyl cyclase 2 |
CN104302324A (en) | 2011-12-08 | 2015-01-21 | 生物测试股份公司 | Uses of immunoconjugates targeting cd138 |
CA2891280C (en) | 2012-11-24 | 2018-03-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
KR102260403B1 (en) | 2013-06-05 | 2021-06-04 | 주식회사 씨앤드씨신약연구소 | Heterocyclic derivatives and use thereof |
KR102344354B1 (en) | 2014-01-10 | 2021-12-28 | 비온디스 비.브이. | Duocarmycin adcs showing improved in vivo antitumor activity |
KR102323301B1 (en) | 2014-01-10 | 2021-11-09 | 비온디스 비.브이. | Method for purifying cys-linked antibody-drug conjugates |
HUE029672T2 (en) | 2014-01-10 | 2017-03-28 | Synthon Biopharmaceuticals Bv | Duocarmycin adcs for use in treatment of endometrial cancer |
ES2960619T3 (en) | 2014-02-28 | 2024-03-05 | Hangzhou Dac Biotech Co Ltd | Loaded Linkers and Their Uses for Conjugation |
WO2015151081A2 (en) | 2015-07-12 | 2015-10-08 | Suzhou M-Conj Biotech Co., Ltd | Bridge linkers for conjugation of a cell-binding molecule |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
KR102459468B1 (en) | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4169888A (en) * | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
US4741900A (en) * | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4912227A (en) * | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
CA1238907A (en) * | 1984-02-21 | 1988-07-05 | Robert C. Kelly | 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds |
CA1260827A (en) * | 1984-08-31 | 1989-09-26 | Richard C. Siegel | Antibody-metal ion complexes |
WO1986001720A1 (en) * | 1984-09-13 | 1986-03-27 | Cytogen Corporation | Antibody therapeutic agent conjugates |
IL82579A0 (en) * | 1986-05-27 | 1987-11-30 | Lilly Co Eli | Immunoglobulin conjugates |
JP2598819B2 (en) * | 1986-12-19 | 1997-04-09 | ジ・アップジョン・カンパニー | New CC-1065 homologs |
NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
-
1991
- 1991-04-24 KR KR1019920702642A patent/KR100208957B1/en not_active IP Right Cessation
- 1991-04-24 CA CA002078118A patent/CA2078118C/en not_active Expired - Fee Related
- 1991-04-24 EP EP91909127A patent/EP0527189A1/en not_active Ceased
- 1991-04-24 AU AU77954/91A patent/AU648313B2/en not_active Ceased
- 1991-04-24 WO PCT/US1991/002704 patent/WO1991016324A1/en not_active Application Discontinuation
- 1991-04-24 JP JP3508837A patent/JPH05508394A/en active Pending
-
1995
- 1995-06-07 US US08/479,231 patent/US5739350A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU648313B2 (en) | 1994-04-21 |
AU7795491A (en) | 1991-11-11 |
US5739350A (en) | 1998-04-14 |
EP0527189A1 (en) | 1993-02-17 |
KR100208957B1 (en) | 1999-07-15 |
JPH05508394A (en) | 1993-11-25 |
CA2078118C (en) | 1999-11-16 |
WO1991016324A1 (en) | 1991-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2078118A1 (en) | Cc-1065 analogs | |
Preud'Homme et al. | Intracytoplasmic and surface-bound immunoglobulins in" nonsecretory" and Bence-Jones myeloma. | |
DK0396387T3 (en) | New antibody delivery system for biological response modifiers | |
DE69636015T2 (en) | BIS-SPECIFIC ANTIBODIES IN WHICH THE BINDING ABILITY IS INHERITIZED BY A MEDIUM-SPLITABLE GROUP REVERSIBLE | |
ZA958444B (en) | Biological active proteins | |
TR200202735T1 (en) | Human monoclonal antibody against AILIM, a co-stimulated signal transduction molecule, and its pharmaceutical use | |
JPS56106154A (en) | Detection method of hemoglobin in night soil | |
DE68925226D1 (en) | Monoclonal antibodies | |
DK0969873T3 (en) | Multiple carbohydrate-containing glycopeptide antigens, vaccine containing them, and use thereof | |
RU94046414A (en) | Monoclonal antibodies to glycoprotein p, their preparing and use, cells producing thereof, immunological diagnostic test based on thereof, therapeutic composition | |
NO870476L (en) | PROCEDURE FOR THE PREPARATION OF CROSS PROTECTIVE HUMAN MONOCLONAL ANTIBODY PREPARATIONS. | |
PT939809E (en) | TIE-2 RECEIVER LIGANDS (TIE LINK 3 AND TIE LINK 4) AND YOUR USES | |
DK0486572T3 (en) | Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof | |
ES2149159T3 (en) | FUSION PROTEINS CONTAINED IN MONOCLONAL ANTIBODIES, LINKER- AND BETA-GLUCURONIDASE, INTENDED FOR THE ACTIVATION OF DRUGS, THEIR PREPARATION AND USE. | |
CA2308007A1 (en) | Enhancer for antibody to lymphocytic tumors | |
SE8800886L (en) | IMMUNGLOBULINKOJUGAT | |
NZ225280A (en) | Human tumor cell epitope and antigen recognised by monoclonal antibody 16-88, the antibody and their use | |
ES8700056A1 (en) | Glycosidic linkage related antigen, process for producing the same and anticancer agent containing the same as effective component. | |
WO1986002651A3 (en) | Specific carbohydrate-binding proteins (lectins) of mammalian tumor cells | |
Serrou et al. | Immune imbalance in cancer patients | |
Strzadala et al. | Differential expression of murine leukemia antigen on L1210 parental and drug-resistant sublines | |
DE59207362D1 (en) | Monoclonal antibodies against the plasmin-antiplasmin complex, process for their preparation and their use | |
Haines et al. | Immunohistochemical Detection of Double-Stranded-RNA-Dependent Protein Kinase (p68) with a Novel Monoclonal Antibody TJ4C4: A Case Report of an AIDS-Associated Kaposi’s Sarcoma Treated with Alpha-Interferon | |
HIGASHIHARA et al. | Serological survey of feline leukemia virus infection and the outcome of antibody-positive cats | |
Lahat et al. | A New T Cell Neoplasm Expressing Surface Anti-DNP Activity, Developed from the Thymus of Mice Bearing MOPC-315 Plasma Cell Tumors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |